知镜 Cognispect · 医学文献与研究工作台

Early and prolonged oral edaravone for neuroprotection in acute ischemic stroke: the ERASE-STROKE randomized controlled phase 3 trial.

Xiang Y, Jin WS, Zhu XC, Song Y, Chen X, Wang QH, Sun HL, Zhao Y, Yu XR, Feng T, Guo AH, Dai HG, Huang HN, Fang JX, Wang MH, Peng YM, Liu XM, Bu XL, Liu YH, Zhang M, Anderson CS, Nogueira RG, He WL, Zhou XF, Wang YJ, ERASE-STROKE investigators.
Science bulletin · 2026-08-22 · PMID 42705987

文献摘要

The optimal timing and duration of neuroprotective therapy for acute ischemic stroke (AIS) remain unclear. Previous studies showed benefits of edaravone treatment when started within 48 h of AIS onset for 14 d, but it remains unknown whether earlier initiation (within 24 h of onset) and longer treatment (28 d) can yield better outcomes. In ERASE-STROKE, oral edaravone (TTYP01) was demonstrated to improve functional outcomes in patients with AIS. Here, to evaluate the neuroprotective effects of TTYP01, a phase 3, multicenter, double-blind trial was conducted among patients with disabling anterior circulation stroke who did not undergo reperfusion therapy. Within 24 h of symptom onset, 614 eligible patients were randomly assigned to receive TTYP01 60 mg or placebo twice daily for 28 d plus standard care. The primary endpoint was excellent functional outcome (mRS score 0-1) at 90 d. Among 614 patients in the intention-to-treat population, excellent outcome was achieved in 65.4% with TTYP01 vs. 47.1% with placebo (odds ratio 2.12; 95% CI 1.53-2.94; P < 0.001). Rates of symptomatic intracranial hemorrhage, mortality, and serious adverse events did not differ significantly. In patients with disabling anterior circulation stroke not receiving reperfusion, 28-d TTYP01 is safe and improves functional recovery. ClinicalTrials.gov: NCT06648304; Chinese Drug Clinical Trial Registry: CTR20230707.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。